Table 1: Drug Utilization Review Board member attendance at the Friday, October 26, 2018 meeting.

<table>
<thead>
<tr>
<th>MEMBER NAME</th>
<th>YES</th>
<th>NO</th>
<th>MEMBER NAME</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. James Barnes</td>
<td></td>
<td>X</td>
<td>Dr. Robert Hogue</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Scott Blaszczyk</td>
<td>X</td>
<td></td>
<td>Dr. Summer Keener</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Mr. Dennis Borel</td>
<td>X</td>
<td></td>
<td>Dr. Alejandro Kudisch</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Deborah Briggs</td>
<td>X</td>
<td></td>
<td>Dr. Jill Lester</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Oscar Brown</td>
<td>X</td>
<td></td>
<td>Dr. Thanhao Ngo</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Deatra Craddock</td>
<td>X</td>
<td></td>
<td>Dr. Richard Noel</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Salil Deshpande</td>
<td></td>
<td>X</td>
<td>Dr. Joseph Vazhappilly</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Laura Ferguson</td>
<td>X</td>
<td></td>
<td>VACANT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Jennifer Fix</td>
<td>X</td>
<td></td>
<td>VACANT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Melbert Hillert</td>
<td>X</td>
<td></td>
<td>VACANT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Drug Utilization Review Board state agency staff attendance at the Friday, October 26, 2018 meeting.

<table>
<thead>
<tr>
<th>STATE AGENCY STAFF NAME</th>
<th>YES</th>
<th>NO</th>
<th>STATE AGENCY STAFF NAME</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Mitchel Abramsky</td>
<td>X</td>
<td></td>
<td>Louisa Cervera</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Aaliya Ahmad, PharmD</td>
<td>X</td>
<td></td>
<td>Joshua Dominguez, PharmD</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Nahid Assadi, RPh</td>
<td>X</td>
<td></td>
<td>Dr. Lisa Glenn</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Maribel O. Castoreno</td>
<td>X</td>
<td></td>
<td>Arshad Qureshi, PharmD</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Table 3: Drug Utilization Review Board contractor attendance at the Friday, October 26, 2018 meeting.

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>YES</th>
<th>NO</th>
<th>CONTRACTOR NAME</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Andrews, Pharm.D. (Magellan Medicaid Administration)</td>
<td>X</td>
<td></td>
<td>Matthew Lennertz, Pharm.D. (Magellan Medicaid Administration)</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Larry Dent Pharm.D., (Conduent)</td>
<td>X</td>
<td></td>
<td>Jennifer Seltzer, Pharm.D. (University of Texas College of Pharmacy)</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Christina Faulkner, Pharm.D. (Health Information Designs, LLC.)</td>
<td>X</td>
<td></td>
<td>Tanner Bain (Health Information Designs, LLC.)</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>
**Additional Item:**
Announcement of two Board members leaving:

1. Dr. Laura Ferguson
2. Dr. Melbert Hillert

Dr. Arshad Qureshi, HHSC, Vendor Drug Program, Drug Utilization Review Formulary Management gave a brief speech and presented the two members with a plaque.

**Agenda Item 1: Call to Order**
Dr. Robert Hogue called the meeting to order at 9:05 a.m. Dr. Hogue introduced and turned the floor over to Ms. Stephanie Gutierrez, HHSC, Advisory Committee Coordination Office. Ms. Gutierrez read meeting logistics and conducted roll call. Ms. Gutierrez noted there was a quorum.

**Agenda Item 2: Approval of minutes from July 27, 2018**
Ms. Gutierrez reminded members a copy of the DRAFT minutes were sent by email as well as can be found in their meeting packet. Ms. Gutierrez opened the floor for discussion. Hearing none, Ms. Gutierrez requested a motion.

**MOTION:** Mr. Dennis Borel motioned to approve the July 27, 2018 minutes with Dr. Alejandro Kudisch seconding the motion. A roll call vote was taken and the minutes were approved unanimously. The motion carried.

**Agenda Item 3: New Member Introductions and Terms**
Ms. Gutierrez announced new members will draw terms for their service on the Board. Ms. Louisa Cervera, HHSC, Drug Utilization Review, Formulary Management Vendor Drug Program Medicaid and CHIP Services, had Dr. Scott Blaszczyk and Dr. Jennifer Fix draw terms. Ms. Gutierrez announced for the record:

1. Dr. Oscar Brown has a four year term ending August 31, 2022
2. Dr. Richard Noel has a two year term ending August 31, 2020
3. Dr. Scott Blaszczyk has a two year term ending August 31, 2020
4. Dr. Jennifer Fix has a four year term ending August 31, 2022
5. Dr. Summer Keener has a two year term ending August 31, 2020

**Agenda Item 4: Ethics Policy Refresher**
Dr. Hogue introduced and turned the floor over to Mr. David Reisman, HHSC, Office of Ethics. Mr. Reisman referenced the PowerPoint and handout, *Ethics Training: Drug Utilization Review Board*.

**Agenda Item 5: Vice-Chair Election**
Dr. Hogue turned the floor over to Ms. Gutierrez for the Officer Election Process. Ms. Gutierrez read the Officer Election Procedure to members. Ms. Gutierrez requested a motion to adopt the Officer Election Procedure.

**MOTION:** Mr. Borel made a motion to adopt the Officer Election Procedure. Dr. Kudish seconded the motion. A roll call vote was taken and the Officer Election Procedure was adopted unanimously. The motion carried.

Ms. Gutierrez implemented the Officer Election Procedure for the election of the Vice-Chair. Ms. Gutierrez read the role and responsibilities of the Vice Chair. Ms. Gutierrez opened the floor to nominations for Vice Chair. Dr. Laura Ferguson nominated Dr. Oscar Brown for Vice Chair. Dr. Brown accepted his nomination. Hearing no other nominations, members wrote the name of their candidate on the ballot. Ms. Gutierrez and Ms. Cervera collected the ballots and tallied the votes. Ms. Gutierrez announced for the record the election of Dr. Brown for Vice Chair.
**Agenda Item 6: New Business**

Dr. Hogue opened the floor to public comment on the drug classes on the therapeutic and clinical drug review for the Medicaid Preferred Drug List. Ms. Gutierrez read Public Comment Announcements to members of the Board and members of the audience. Dr. Hogue reviewed the classes of drugs for public comment. The following individuals provided testimony to the Board and answered questions:

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Representing</th>
<th>Recommendations</th>
<th>PDL Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Phillips</td>
<td>Cerecor</td>
<td>Karbinal ER, Poly-Vi-Flor</td>
<td>Antihistamines, First Generation, Pediatric vitamin preparation</td>
</tr>
<tr>
<td>Phillip Lai</td>
<td>Otsuka</td>
<td>Abilify Maintena, Rexulti</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Karen Inzurriaga</td>
<td>Self</td>
<td>Abilify Maintena</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Kenneth Beury</td>
<td>Alkermes</td>
<td>Aristada</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Valerie Ng</td>
<td>Indivior</td>
<td>Perseris</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Peter Dorson</td>
<td>Janssen</td>
<td>Invega Sustenna, Invega Trinza</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Michael Nelson</td>
<td>Sunovion</td>
<td>Latuda</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Thomas Weiss</td>
<td>Allergan</td>
<td>Vraylar</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Greg Hansch</td>
<td>NAMI Texas</td>
<td>Open access to antipsychotics</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Scott Budsberg</td>
<td>Amgen</td>
<td>Enbrel</td>
<td>Cytokine And Cam Antagonists</td>
</tr>
<tr>
<td>Laura Hill</td>
<td>Abbvie</td>
<td>Humira</td>
<td>Cytokine And Cam Antagonists</td>
</tr>
<tr>
<td>Anne DePriest</td>
<td>Janssen</td>
<td>Tremfya</td>
<td>Cytokine And Cam Antagonists</td>
</tr>
<tr>
<td>Gia McLean</td>
<td>Celgene</td>
<td>Otezla</td>
<td>Cytokine And Cam Antagonists</td>
</tr>
<tr>
<td>Anthony Colavecchia</td>
<td>Pfizer</td>
<td>Xeljanz, Xeljanz XR</td>
<td>Cytokine And Cam Antagonists</td>
</tr>
<tr>
<td>Jeniffer Ward</td>
<td>Lilly</td>
<td>Olumiant, Taltz</td>
<td>Cytokine And Cam Antagonists</td>
</tr>
</tbody>
</table>

**Break**

Dr. Hogue announced a 10 minute break.
**Agenda Item 6: New Business Continued**  
Dr. Hogue reconvened the meeting at 10:58 a.m.  

Dr. Hogue re-opened the floor to public comment. The following individuals provided testimony to the Board and answered questions:
<table>
<thead>
<tr>
<th>Speaker</th>
<th>Representing</th>
<th>Recommendations</th>
<th>PDL Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kate Kim</td>
<td>Synergy</td>
<td>Trulance</td>
<td>GI Motility Chronic</td>
</tr>
<tr>
<td>Kirsten Mar</td>
<td>Astra Zeneca</td>
<td>Movantik</td>
<td>GI Motility Chronic</td>
</tr>
<tr>
<td>Jignesh Patel</td>
<td>Novo Nordisk</td>
<td>Norditropin Flexpro</td>
<td>Growth Hormone</td>
</tr>
<tr>
<td>Thomas Shank</td>
<td>Pfizer</td>
<td>Genotropin</td>
<td>Growth Hormone</td>
</tr>
<tr>
<td>Sean Burn</td>
<td>Gilead</td>
<td>Epclusa</td>
<td>Hepatitis C agents</td>
</tr>
<tr>
<td>Laura Hill</td>
<td>Abbvie</td>
<td>Mavyret</td>
<td>Hepatitis C agents</td>
</tr>
<tr>
<td>Prasun K. Jahal</td>
<td>Baylor College</td>
<td>Change Prior</td>
<td>Hypoglycemics, Incretin</td>
</tr>
<tr>
<td></td>
<td>of Medicine</td>
<td>authorization</td>
<td>Mimetics/Enhancers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>requirements</td>
<td></td>
</tr>
<tr>
<td>Courtney Walker</td>
<td>Novo Nordisk</td>
<td>Victoza, Tresiba</td>
<td>Hypoglycemics, Incretin</td>
</tr>
<tr>
<td>Kirsten Mar</td>
<td>AstraZeneca</td>
<td>Bydureon BCise</td>
<td>Hypoglycemics, Incretin</td>
</tr>
<tr>
<td>Kirsten Mar</td>
<td>AstraZeneca</td>
<td>Farxiga</td>
<td>Hypoglycemics, SGLT2</td>
</tr>
<tr>
<td>Anne DePriest</td>
<td>Janssen</td>
<td>Invokana</td>
<td>Hypoglycemics, SGLT2</td>
</tr>
<tr>
<td>Aimee Kraus</td>
<td>Pfizer</td>
<td>Eucrisa</td>
<td>Immunomodulators, Atopic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermatitis</td>
</tr>
<tr>
<td>Syed Ali</td>
<td>Acclaim Dermatology</td>
<td>Eucrisa</td>
<td>Immunomodulators, Atopic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermatitis</td>
</tr>
<tr>
<td>Johanna Purcell</td>
<td>Aerie</td>
<td>Rhopressa</td>
<td>Ophthalmics, Glaucoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Agents</td>
</tr>
<tr>
<td>Geri Lynn Utter</td>
<td>Orexo</td>
<td>Zubsolv</td>
<td>Opiate Dependence Treatments</td>
</tr>
<tr>
<td>Valerie Ng</td>
<td>Indivior</td>
<td>Sublocade</td>
<td>Opiate Dependence Treatments</td>
</tr>
<tr>
<td>Matt Rysavy</td>
<td>US World Meds</td>
<td>Lucemyra</td>
<td>Opiate Dependence Treatments</td>
</tr>
<tr>
<td>Deirdre Browne</td>
<td>MHMR Tarrant</td>
<td>Vivitrol</td>
<td>Opiate Dependence Treatments</td>
</tr>
<tr>
<td>Kenneth Beury</td>
<td>Alkermes</td>
<td>Vivitrol</td>
<td>Opiate Dependence Treatments</td>
</tr>
<tr>
<td>Carl F. Hunter</td>
<td>Self</td>
<td>Open access to OUD</td>
<td>Opiate Dependence Treatments</td>
</tr>
<tr>
<td></td>
<td></td>
<td>treatments</td>
<td></td>
</tr>
</tbody>
</table>

Drug Utilization Review Board • October 26, 2018 • Meeting Minutes • Page 5 of 8
Dr. Hogue turned the floor over to Dr. Matt Lennertz, Magellan Medicaid Administration, MMA. Dr. Lennertz reviewed points of the classes that have not been brought up by Public Comment or previous meetings.

**Agenda Item 7: Executive Work Session**
Dr. Hogue announced the Board will go into closed session at 1:10 p.m. Dr. Hogue read the legislation granting the Board the ability to meet in executive session.

**Agenda Item 8: Announcements of drugs recommended for the Medicaid PDL**
Dr. Hogue reconvened the meeting from executive session at 3:15 p.m. Dr. Hogue turned the floor over to Dr. Lennertz. Dr. Lennertz reviewed, for the record, the proposed recommendations decided by the Board in executive session. Dr. Lennertz referenced the PowerPoint, *Texas Medicaid Drug Utilization Review Board October 26, 2018*.

Dr. Hogue requested a motion.

**MOTION**: Dr. Ferguson motioned to approve and accept the proposed recommended drug list. Dr. Fix seconded. A roll call vote was taken and the motioned carried unanimously.

**Agenda Item 9: Retrospective DUR**
Dr. Hogue introduced and turned the floor over to Dr. Larry Dent, Board Certified Pharmacotherapy Specialist, Conduent, LLC. Dr. Dent referenced the PowerPoint and handout, *Texas DUR Board Meeting*.

**Agenda Item 9a: Report on recent retrospective DUR interventions**
Dr. Dent covered the report of recent interventions:

1. The intervention letters for, Benzodiazepines Anxiolytics and Controlled Sedative Hypnotics were mailed out on 7/12/2018 to 72 providers, impacting 59 patients.
2. The Diabetes Disease Management intervention letters were mailed out in 8/13/2018 to 3,572 providers, impacting 4,516 patients.
3. The Rheumatoid Arthritis Management intervention letters were mailed out in 8/22/2018 to 287 prescribers, impacting 253 patients.

**Agenda Item 9b: Report on recent retrospective DUR outcomes**
Dr. Dent reported on the both the cost savings and the clinical outcomes associated with the following interventions:
1. Opioids Use During Pregnancy
2. Polypharmacy
3. Stroke Prevention

**Agenda Item 9c: Retrospective DUR proposals**
Dr. Dent proceeded with retrospective DUR proposals.

**Agenda Item 9ci: Management of psychotropic drugs in adults**
Dr. Dent highlighted the following performance indicators:
1. High Dose Attention Deficit and Hyperactivity Disorder (ADHD) Medications
2. ADHD Medications without indication
3. High dose antidepressants
4. High dose second generation antipsychotics (SGA)
5. Multiple (3 or more) oral SGAs
6. Psychotropic polypharmacy (4 or more psychotropic medications)
7. Monitoring of glucose and/or hemoglobin A1c in patients on SGAs
8. Monitoring lipids in patients on SGAs
9. Concomitant use of oral antipsychotics with a long-acting injectable antipsychotic for greater than 90 days.

Ms. Gutierrez read Public Comment Announcements to members of the Board and members of the audience.

Dr. Hogue requested a motion on the proposed interventions.

**MOTION**: Dr. Noel made a motion to approve the retrospective study as presented with the change to use the maximum dose as per the Texas standard rather than what is in the package insert. Dr. Ferguson seconded the motion. A roll call vote was taken and the motioned carried unanimously.

**Agenda Item 9cii: Medication adherence**
Dr. Dent focused on the following drug classes:
1. Inhaled corticosteroids
2. Anticonvulsants
3. Antidepressants
4. Oral antidiabetics
5. Antihypertensive
6. Antilipemics
7. Oral SGAs
8. Inhaled drugs for treatment of Chronic Obstructive Pulmonary Disease (COPD)
9. Thyroid replacement drugs

Dr. Hogue requested a motion.

**MOTION**: Dr. Brown motioned to table medication adherence to the next meeting and rather make a process of the Board to provide advice as to the type of questions that are best to ask. Dr. Fix seconded the motion. A roll call vote was taken and the motioned carried unanimously.
**ACTION ITEM**: Dr. Ferguson will send the recommendations to staff.

**Agenda Item 10: Prospective prior authorization proposals (clinical edits)**
Dr. Hogue introduced and turned the floor over to Dr. Christina Faulkner, Health Information Designs, LLC. Dr. Faulkner referenced the PowerPoint and handout, *Texas HHSC DUR Board Meeting October 26, 2018.*

**Agenda Item 10a: Calcitonin gene-related peptide receptor (CGRP) Antagonist - new criteria**
Dr. Faulkner presented an overview of the Aimovig® drug information, the guidelines for the prevention of episodic migraine in adults, and the Calcitonin Gene-Related Peptide receptor (CGRP) clinical PA approval criteria.
Dr. Hogue opened the floor to public comment.
Dr. Hogue requested a motion.

**MOTION**: Dr. Brown made a motion to approve the CGRP clinical Prior Authorization proposals as amended. Dr. Briggs seconded the motion. A roll call vote was taken. The motioned carried with one objection by Dr. Fix.

Dr. Hogue stated for the recorded the remaining agenda items will be postponed until the next meeting.

**Agenda Item 11: Adjournment**
Dr. Hogue adjourned the meeting at 4:23 p.m.

The webcasting link is: [https://texashhsc.swagit.com/play/10262018-781](https://texashhsc.swagit.com/play/10262018-781)